
- /
- Supported exchanges
- / US
- / EXAS.NASDAQ
EXACT Sciences Corporation (EXAS NASDAQ) stock market data APIs
EXACT Sciences Corporation Financial Data Overview
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get EXACT Sciences Corporation data using free add-ons & libraries
Get EXACT Sciences Corporation Fundamental Data
EXACT Sciences Corporation Fundamental data includes:
- Net Revenue: 2 759 M
- EBITDA: 29 761 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-02-19
- EPS/Forecast: -0.3327
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
EXACT Sciences Corporation News

Certara, Inc. (CERT) Earnings Expected to Grow: Should You Buy?
Certara, Inc. (CERT) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook gives...


This Exact Sciences Insider Increased Their Holding In The Last Year
From what we can see, insiders were net buyers in Exact Sciences Corporation's (NASDAQ:EXAS ) during the past 12 months. That is, insiders acquired the stock in greater numbers than they sold it. Whi...

Exact Sciences (EXAS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Wall Street expects a year-over-year increase in earnings on higher revenues when Exact Sciences (EXAS) reports results for the quarter ended March 2025. While this widely-known consensus outlook is i...

Exact Sciences (EXAS): Among Billionaire George Soros’ Small-Cap Stocks with Huge Upside Potential
We recently published a list of Billionaire George Soros’ 10 Small-Cap Stocks with Huge Upside Potential. In this article, we are going to take a look at where Exact Sciences Corporation (NASDAQ:EXA...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.